-
Accuray Reports Fiscal 2024 Third Quarter Financial Results
02 May 2024 14:18 GMT
MADISON, Wis., May 1, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024.
Third Quarter Fiscal 2024 Summary
Net revenue of $101.1 million decreased 14 …
-
Bio-Techne Corporation (NASDAQ:TECH) Q3 2024 Earnings Call Transcript
02 May 2024 14:50 GMT
… to report that our third quarter outperformed our initial … Starting with the overall third quarter financial performance. Adjusted EPS … capital expenditures was $16.4 million. Also during Q3, we … Thank you, Puneet. Regarding pharma and the early funding, thank …
-
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
02 May 2024 10:11 GMT
… that commenced in the third quarter of 2023.
Total … flow available for discretionary expenditures. For example, free …
About Aurinia
Aurinia Pharmaceuticals is a fully … 013
142,641
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED …
-
Ashland reports financial results1 for second quarter fiscal 2024; issues outlook for third quarter and full-year fiscal 2024
30 Apr 2024 21:01 GMT
… its outlook for third quarter and full-year fiscal … consumer-focused markets including pharmaceuticals, personal care and … Overall, for the fiscal-third quarter the company expects sales … of mandatory versus discretionary expenditures can vary significantly …
-
ResMed Inc. (NYSE:RMD) Q3 2024 Earnings Call Transcript
30 Apr 2024 17:42 GMT
… third quarter (see the details here). Operator: Hello. And welcome to the Q3 … Welcome to ResMed’s third quarter fiscal year 2024 earnings … -line therapies, including pharmaceutical options. We’re … capital position. Capital expenditure for the quarter was …
-
West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2024 Earnings Call Transcript
30 Apr 2024 13:38 GMT
… Transcript April 25, 2024
West Pharmaceutical Services, Inc. beats earnings … at the end of the third quarter (see the details here). … repurchases and/or capital expenditures offset by cash from operations … that as we go into Q3 and Q4 throughout the …
-
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
29 Apr 2024 11:16 GMT
… to close in the third quarter of 2024, subject … counsel.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical … vi) unanticipated difficulties or expenditures relating to the proposed … a trademark of Deciphera Pharmaceuticals, LLC.
Additional …
-
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
27 Apr 2024 02:56 GMT
… They contain information on pharmaceuticals, including compounds under development, … resources. R&D expenditure was on track. Core … forecast revised in the third quarter. Commercial lives covered, … in second quarter or third quarter, depending on the …
-
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
02 May 2024 12:54 GMT
… health care providers and pharmacies to increase vaccination coverage … first established in the third quarter of 2023. The Company … assets prior to the third quarter of 2023.
Net Income … be negligible.
Capital Expenditures: Capital expenditures for 2024 are …
-
WW International, Inc. Announces First Quarter 2024 Results
02 May 2024 20:01 GMT
End of Period Subscribers of 4.0 million, including 91 thousand End of Period Clinical Subscribers
Revenues of $206.5 million
Gross margin of 66.7%; excluding the net impact of restructuring charges related to prior year restructuring plans, adjusted gross …